Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 24 November 2014 | By Alexander Gaffney, RAC,
US regulators today announced major restrictions on laparoscopic power morcellator (LPM) devices following major concerns that the devices could be harming patients.
The restrictions, announced on 24 November 2014 by the US Food and Drug Administration (FDA), follow months of major concern that the devices could be harming women more than they helped. Power morcellators were primarily used to remove non-cancerous uterine fibroids by morcellating the tissue (i.e. chopping it up into smaller pieces), allowing the fibroids to be removed through a small incision.
However, reports in the Wall Street Journal and other outlets found evidence the devices were actually contributing to the spread of undiagnosed cancerous cells in some cases, leading to fatal outcomes for some women. In April 2014, FDA warned the public of this link, and discouraged their use in most cases.
FDA said it estimated that approximately one in every 350 women undergoing an LPM procedure has an "unsuspected uterine sarcoma, a type of uterine cancer." The morcellator could spread this cancerous tissue, FDA noted.
While some advocates pushed for an outright ban on the devices, some healthcare providers pushed back, saying there is a small subset of women for whom other surgical options are either ineffective or more dangerous than LPM.
FDA's latest restrictions, outlined in its guidance document, Product Labeling for Laparoscopic Power Morcellators, are meant to "promote the safe and effective use of LPMs when used for gynecologic surgeries," FDA wrote.
Effective immediately, LPMs will need to be labeled with both a prominent warning and two contraindications:
CONTRAINDICATION: Laparoscopic power morcellators are contraindicated in gynecologic surgery in which the tissue to be morcellated is known or suspected to contain malignancy.CONTRAINDICATION: Laparoscopic power morcellators are contraindicated for removal of uterine tissue containing suspected fibroids in patients who are: peri- or post-menopausal, orcandidates for en bloc tissue removal, for example, through the vagina or via a mini-laparotomy incision. WARNING: Uterine tissue may contain unsuspected cancer. The use of laparoscopic power morcellators during fibroid surgery may spread cancer, and decrease the long-term survival of patients. This information should be shared with patients when considering surgery with the use of these devices.
CONTRAINDICATION: Laparoscopic power morcellators are contraindicated in gynecologic surgery in which the tissue to be morcellated is known or suspected to contain malignancy.
CONTRAINDICATION: Laparoscopic power morcellators are contraindicated for removal of uterine tissue containing suspected fibroids in patients who are:
WARNING: Uterine tissue may contain unsuspected cancer. The use of laparoscopic power morcellators during fibroid surgery may spread cancer, and decrease the long-term survival of patients. This information should be shared with patients when considering surgery with the use of these devices.
The new warnings will preclude the "vast majority of women" from ever having the devices used on them, FDA said in a statement.
Still, FDA said it will be monitoring adverse event reports and other data to determine if "further action," including a ban on the devices, is necessary.
FDA Statement
Product Labeling for Laparoscopic Power Morcellators (FR)
Tags: Power Morcellator, Laparoscopic Power Morcellator, Guidance, Guidance in Immediate Effect, IIE Guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.